Osimertinib - Globe Thesis

Keyword [Osimertinib] Result: 21 - 40 \| Page: 2 of 3
21.	The Efficacy And Safety Of Patients With EGFR-T790M Mutation-positive Advanced Non-small Cell Lung Cancer With Different Sources Osimertinib Treatment
22.	Application Of Osimertinib In EGFR-mutant Non-small Cell Lung Cancer With Leptomeningeal Metastases
23.	Analysis Of The Efficacy And Related Factors Of Osimertinib After The First Generation EGFR-TKIs In Advanced Lung Adenocarcinoma With T790M Positive
24.	Identification And Functional Study Of Acquired Resistance Markers Of Third-generation EGFR-TKI Osimertinib
25.	Targeting DNA-PK Overcomes Acquired Resistance To Third-Generation EGFR-TKi Osimertinib In Non-Small Cell Lung Cancer
26.	Investigation On Anti-tumor Activity Of CDK4/6 Inhibitor In Non-small Cell Lung Cancer Cell Lines And The Mechanism Of Overcoming The Third Generation EGFR-TKI Acquired Resistance
27.	Clinical Outcome And Resistance Mechanism Of Osimertinib In EGFR-mutated Advanced Non-Small-Cell Lung Cancer
28.	Study On Molecular Analyses And Drug Sensitive Tests Of Organoids Optimized Therapy In Patients Of Non-small Cell Lung Cancer With Acquried EGFR T790M And Resisted To Osimertinib
29.	Evolution Of Immune Microenvironment And Mechanism Of Drug Resistance In EGFR L858R/T790M Co-mutant Non-small Cell Lung Cancer With Osimertinib Treatment
30.	IGFBP7 Involves In Acquired Resistance To Osimertinib In Non-small Cell Lung Cancer
31.	Influence Of ACK1 Inhibitor On Drug Sensitivity To Osimertinib In EGFR Mutant Non-small Cell Lung Cancer
32.	Study On The Mechanism Of ABCG2 In Osimertinib Resistant Non-small Cell Lung Cancer
33.	Efficacy And Influencing Factors Of Double-dose Ectinib In Patients With Advanced Non-small Cell Lung Cancer Harboring EGFRexon 21-L858R Mutation
34.	Explore The Rate And Risk Factors For Radiation Pneumonitis In Non-small Cell Lung Cancer Patients Treated With EGFR-TKI And Thoracic Radiotherapy
35.	Analysis Of Prognostic Factors Of Osimertinib Mesylate In The Treatment Of Brain Metastases From EGFR Gene Mutant Non-small Cell Lung Cancer
36.	The Efficacy And Mechanism Of Osimertinib Plus Bevacizumab In Leptomeningeal Metastasis With EGFR Mutant Non-Small Cell Lung Cancer
37.	Comparison Of The Efficacy Of Osimertinib And Bevacizumab In Patients With EGFR Mutation Positive Non-small Cell Lung Cancer And Leptomeningeal Metastasis
38.	Comparison Of The Efficacy And Safety Of Afatinib And Osimertinib In The Treatment Of EGFR Exon20 Insertions Mutation Non-small Cell Lung Cancer :a Meta-analysis
39.	Cancer-associated Fibroblasts Overexpressing GPER1 Induce Osimertinib Resistance In Non-small Cell Lung Cancer Through TGF-?2
40.	Observation On The Efficacy Of Osimertinib Combined With Anti-angiogenic Drugs In Advanced NSCLC Patients With T790M Mutation After First-generation EGFR-TKIs Resistance
<<First <Prev Next> Last>> Jump to